| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.11.25 | Listing of subscription rights and paid subscription shares of Bioextrax AB | 204 | GlobeNewswire | With effect from November 27, 2025, the subscription rights in Bioextrax AB will be traded on First North Growth Market. Trading will continue up until and including December 08, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| BIOEXTRAX Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.11.2025 | 190 | Xetra Newsboard | Das Instrument WTGA IE000TB3YTV4 WSDMTR.GL AUTO.INNO.DLACC ETF wird cum Kapitalmassnahme gehandelt am 24.11.2025 und ex Kapitalmassnahme am 25.11.2025 The instrument WTGA IE000TB3YTV4 WSDMTR.GL AUTO.INNO.DLACC... ► Artikel lesen | |
| 20.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 20.11.2025 | 300 | Xetra Newsboard | Das Instrument 6QZ AU0000107211 TOMBADOR IRON LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 20.11.2025 und ex Kapitalmassnahme am 21.11.2025 The instrument 6QZ AU0000107211 TOMBADOR IRON LTD. EQUITY... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,298 | +0,66 % | Valneva zieht US-Zulassungsanträge für IXCHIQ zurück - Aktie unter Druck | Die Valneva SE hat die Zulassungsanträge (BLA und IND) für ihren Chikungunya-Impfstoff IXCHIQ in den USA freiwillig zurückgezogen. Hintergrund sind regulatorische Maßnahmen der U.S. Food and Drug Administration... ► Artikel lesen | |
| AMGEN | 293,55 | -0,14 % | Ember LifeSciences Taps Former Amgen Exec as CFO | ||
| EPIGENOMICS | 0,900 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| STRYKER | 310,10 | -0,13 % | Teledyne FLIR Defense Wins $32 Million Contract to Provide Recon Surveillance Kit on Strykers for Bulgaria | Advanced sensor suite will add situational awareness capabilities to Stryker armored vehicles, including 360-degree visibility, thermal imaging, and long-range threat detection
Teledyne FLIR Defense... ► Artikel lesen | |
| OCUGEN | 1,324 | +3,52 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| BIO-GATE | 0,820 | -0,61 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,390 | +0,55 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| 10X GENOMICS | 19,295 | -0,54 % | 10x Genomics, Inc.: 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results | PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited... ► Artikel lesen | |
| USANA HEALTH SCIENCES | 19,000 | 0,00 % | Kevin Guest kehrt als CEO zu USANA Health Sciences zurück | ||
| BIO-TECHNE | 58,50 | -4,88 % | Research and Markets: GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among Others - ResearchAndMarkets.com | The "GMP Cytokine Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering.
The global GMP cytokine market is expected to grow with... ► Artikel lesen | |
| INNATE PHARMA | 1,568 | 0,00 % | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| VERACYTE | 35,800 | -3,76 % | Veracyte, Inc.: Veracyte to Participate in Upcoming Investor Conferences | Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
Wolfe Research Healthcare Conference New York... ► Artikel lesen | |
| PROTARA THERAPEUTICS | 4,040 | -18,22 % | Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations | NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today... ► Artikel lesen | |
| XENON PHARMACEUTICALS | 35,400 | +0,57 % | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| NUCANA | 3,270 | 0,00 % | NuCana plc: NuCana Appoints Theresa Bruce as Chief Operating Officer | EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes... ► Artikel lesen |